UB-612 Vaccine

UB-612 Vaccinea
United Biomedical, Inc., Asia

UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine developed by UBI/UBIA Group. UB-612 includes a S1-RBD-sFc fusion protein formulated with Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II. These Th and CTL peptides are selected based on their predicted binding to human MHC I and II, which would allow for the induction of memory recall and T-cell activation and effector functions. To date, preclinical studies in guinea pigs, rats and mice have shown that UB-612 generated extremely high titers of neutralizing antibodies with S1-RBD:hACE2 inhibition activities, as well as a balanced Th1/Th2 response toward the Th1 polarity. UB-612 is expected not only to be safe but also to induce high titers of neutralizing antibodies and provide T cell memory for a long lasting protection against COVID-19 across all human subjects irrespective of age, sex and ethnicities.

Epidemic Prevention Advantage：
1. Is a proprietary high-precision designer S1-RBD-protein based vaccine developed by UBI/UBIA Group.
2. The vaccine includes a S1-RBD-sFc fusion protein formulated with proprietary Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
3. Preclinical studies have shown that the vaccine can generate extremely high titers of neutralizing antibodies as well as a balanced Th1/Th2 response toward the Th1 polarity.
4. Is expected not only to be safe but also to induce high titers of neutralizing antibodies and provide T cell memory for a long lasting protection against COVID-19 in humans.
5. UBI Group has its own vaccine production facility and has planned to produce 50 million to 100 million doses of vaccines before the first quarter of 2021 to provide public health emergency needs.

Collaboration Options：R&D collaboration, investment collaboration